title: What is the greatest regulatory challenge in the translation of biomaterials to the clinic?
abstract: Leaders in the field comment on what they perceive to be the greatest barriers to biomaterial translation.
authors.affiliation: Department of Medicine, University of Utah, Salt Lake City, UT 84108, USA. glenn.prestwich@pharm.utah.edu
authors.forename: Glenn D
authors.initials: GD
authors.lastname: Prestwich
authors.forename: Sangeeta
authors.initials: S
authors.lastname: Bhatia
authors.forename: Christopher K
authors.initials: CK
authors.lastname: Breuer
authors.forename: Shannon L M
authors.initials: SL
authors.lastname: Dahl
authors.forename: Chris
authors.initials: C
authors.lastname: Mason
authors.forename: Richard
authors.initials: R
authors.lastname: McFarland
authors.forename: David J
authors.initials: DJ
authors.lastname: McQuillan
authors.forename: Jonathan
authors.initials: J
authors.lastname: Sackner-Bernstein
authors.forename: Jeffrey
authors.initials: J
authors.lastname: Schox
authors.forename: William E
authors.initials: WE
authors.lastname: Tente
authors.forename: Alan
authors.initials: A
authors.lastname: Trounson
mesh_terms: D000818:Animals; D001672:Biocompatible Materials / Q000737:chemistry*; D001709:Biotechnology / Q000379:methods / Q000639:trends; D006801:Humans; D023822:Tissue Engineering / Q000379:methods / Q000639:trends; D057170:Translational Research, Biomedical / Q000379:methods* / Q000639:trends; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D001672:Biocompatible Materials